Harnessing the immune system to target pathological tau protein has recently become attractive as a potential therapy for Alzheimer's disease (AD) and related tauopathies. We previously showed that active immunization targeting a disease-related phospho-tau epitope reduces cerebral tau aggregates in vivo and slows progression of the tangle-related behavioral phenotype. The promise of tau immunotherapy has now been confirmed by other groups. Recent reports that extracellular tau is important for the anatomical spread of tau pathology strengthen as well the feasibility of clearing pathological tau. While the active approach is in many ways ideal for a chronic disease such as AD, it can inherently lead to autoimmune adverse reactions that may be avoided with passive immunization. It also remains to be thoroughly assessed if a similar therapeutic effect can be obtained with tau monoclonal antibodies (mAbs) alone, as our preliminary findings indicate. These monoclonals should then be humanized for clinical trials.
Specific Aim 1 is to determine if the efficacy, safety and mechanism of action of tau mAbs is epitope- dependent. We hypothesize that antibody efficacy in clearing tau aggregates may depend on the epitope being targeted and the stage of tau pathology. The ability of monoclonals against various tau epitopes to prevent or reverse tau aggregation, and associated toxicity and cognitive impairments will be assessed in a novel tangle mouse model that is ideal for this purpose. Concurrently, the mechanism and safety of antibody-mediated clearance of pathological tau will be clarified in live animals and brain slice cultures. Prevention or reversal of tau aggregation and/or downstream pathology may be epitope dependent. Certain tau epitopes are more prominently detected in the early stages of tau aggregation whereas other are generated and/or become accessible for antibody-binding in the later stages of the disease. It is also conceivable that targeting some regions of tau may have toxic effects. These studies are likely to have broad implications. They may clarify sequence of events involved in tau pathology, and identify which regions of the tau protein is best to target for immunotherapy, which may apply to other therapies as well. Furthermore, these experiments should identify a candidate monoclonal for clinical trials.
Specific Aim 2 is structural characterization of the lead therapeutic tau mAb for its humanization. This procedure is necessary to reduce the immunogenicity of the antibody, and thereby render it safer for human use. It requires structural characterization of its binding site, and regions not critical for antigen binding can then be replaced with human sequences. The important structural information can also facilitate development of small molecule mimetics for therapeutic or diagnostic use. Together, these aims may lead to a novel therapy for AD and related tauopathies.

Public Health Relevance

The Aims are to determine if the efficacy, safety and mechanism of action of tau monoclonals is dependent on which region of the tau molecule in tauopathies is being targeted. Subsequently, the structure of the lead antibody will be characterized so that it can in future studies be humanized for clinical trials in individuals with Alzheimer's disease or other tauopathies. Hence, this research is very relevant to public health.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS077239-04
Application #
8661797
Study Section
Cellular and Molecular Biology of Neurodegeneration Study Section (CMND)
Program Officer
Corriveau, Roderick A
Project Start
2011-09-01
Project End
2017-05-31
Budget Start
2015-06-01
Budget End
2016-05-31
Support Year
4
Fiscal Year
2015
Total Cost
$449,080
Indirect Cost
$183,491
Name
New York University
Department
Neurosciences
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Bertrand, Anne; Baron, Maria; Hoang, Dung M et al. (2018) In Vivo Evaluation of Neuronal Transport in Murine Models of Neurodegeneration Using Manganese-Enhanced MRI. Methods Mol Biol 1779:527-541
Chukwu, Jessica E; Pedersen, Jan T; Pedersen, Lars Ø et al. (2018) Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein. Sci Rep 8:6209
Krishnaswamy, Senthilkumar; Wu, Qian; Lin, Yan et al. (2018) In Vivo Imaging of Tauopathy in Mice. Methods Mol Biol 1779:513-526
Wu, Qian; Lin, Yan; Gu, Jiaping et al. (2018) Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging. EBioMedicine 35:270-278
Shamir, Dov B; Deng, Yan; Sigurdsson, Einar M (2018) Live Imaging of Pathological Tau Protein and Tau Antibodies in a Neuron-Like Cellular Model. Methods Mol Biol 1779:371-379
Sigurdsson, Einar M (2018) Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls. J Alzheimers Dis 64:S555-S565
Congdon, Erin E; Sigurdsson, Einar M (2018) Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 14:399-415
Rajamohamedsait, Hameetha; Rasool, Suhail; Rajamohamedsait, Wajitha et al. (2017) Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-? Pathologies in 3xTg Mice. Sci Rep 7:17034
Klionsky, Daniel J (see original citation for additional authors) (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1-222
Krishnamurthy, Pavan K; Rajamohamedsait, Hameetha B; Gonzalez, Veronica et al. (2016) Sex and Immunogen-Specific Benefits of Immunotherapy Targeting Islet Amyloid Polypeptide in Transgenic and Wild-Type Mice. Front Endocrinol (Lausanne) 7:62

Showing the most recent 10 out of 31 publications